Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors.
暂无分享,去创建一个
A. Friedman | D. Bigner | G. Dranoff | H. Friedman | J. Sampson | G. Archer | D. Ashley | L. Hale | G Dranoff | H S Friedman | D D Bigner | A H Friedman | C. Wikstrand | D M Ashley | C. Small | L. Crotty | S. Lee | G. Archer | C J Wikstrand | J H Sampson | L E Crotty | S Lee | G E Archer | L P Hale | C Small | Samson Lee | A. Friedman
[1] J. Biegel,et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. , 1995, Cancer research.
[2] J. Becker,et al. An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[3] K. Okumura,et al. Expression of Fcγ Receptors on Astroglial Cell Lines and Their Role in the Central Nervous System , 1992 .
[4] W. Walker. Origins of macrophage diversity: functional and phenotypic analysis of cloned populations of mouse splenic macrophages. , 1987, Cellular immunology.
[5] W. Cavenee,et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[6] R. Coleman,et al. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Hermona Soreq,et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin , 1985, Nature.
[8] H. Bloom,et al. Glioblastoma Multiforme: A Controlled Trial to Assess the Value of Specific Active Immunotherapy in Patients Treated by Radical Surgery and Radiotherapy , 1973, British Journal of Cancer.
[9] P F Morrison,et al. Convection-enhanced delivery of macromolecules in the brain. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[10] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[11] G. Giuliani,et al. Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas , 1997, Cancer.
[12] K. Gollahon,et al. Immunoglobulin bound in vivo to Fc receptor-positive cells in human central nervous system tumors. , 1980, Journal of the National Cancer Institute.
[13] C. James,et al. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[14] D. Bigner,et al. Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. , 1993, Cancer research.
[15] H. Magdelenat,et al. A phase I study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas. , 1996, Neurosurgery.
[16] H. Koprowski,et al. Tumors undergoing rejection induced by monoclonal antibodies of the IgG2a isotype contain increased numbers of macrophages activated for a distinctive form of antibody-dependent cytolysis. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[17] T. Roszman,et al. Inability of mitogen-activated lymphocytes obtained from patients with malignant primary intracranial tumors to express high affinity interleukin 2 receptors. , 1990, The Journal of clinical investigation.
[18] W. Hickey,et al. Monoclonal antibody analysis of MHC expression in human brain biopsies: tissue ranging from "histologically normal" to that showing different levels of glial tumor involvement. , 1986, Journal of immunology.
[19] C. James,et al. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[20] H. Koprowski,et al. IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[21] M. Schrappe,et al. Immunotherapy of human glioma xenografts with unlabeled, 131I-, or 125I-labeled monoclonal antibody 425 to epidermal growth factor receptor. , 1992, Cancer research.
[22] E. Jaffee,et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[23] A. Olivier,et al. Fc Receptors for IgG on Cultured Human Microglia Mediate Cytotoxicity and Phagocytosis of Antibody-coated Targets , 1994, Journal of neuropathology and experimental neurology.
[24] D Tripathy,et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] M. Lubeck,et al. Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells. , 1983, Science.
[26] P. Leder,et al. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. , 1992, Science.
[27] P. Humphrey,et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[28] R. Mulligan,et al. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[29] P. Humphrey,et al. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[30] K. A. Wall,et al. Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule. , 1983, Journal of immunology.
[31] M. Netsky,et al. DEPRESSED CELL-MEDIATED IMMUNITY IN PATIENTS WITH PRIMARY INTRACRANIAL TUMORS , 1972, The Journal of experimental medicine.
[32] V. Devita,et al. Biologic Therapy of Cancer , 1992 .
[33] P. Humphrey,et al. Investigation of a synthetic peptide as immunogen for a variant epidermal growth factor receptor associated with gliomas , 1993, Journal of Neuroimmunology.
[34] A. Sutter,et al. Antibody-mediated tumor cytotoxicity of microglia. , 1991, Pathobiology : journal of immunopathology, molecular and cellular biology.
[35] R K Jain,et al. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. , 1990, Cancer research.
[36] E. Oldfield,et al. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors , 1997, Nature Medicine.
[37] D. Bigner,et al. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[38] J. Kurtzberg,et al. Determinants of deoxyadenosine toxicity in hybrids between human T- and B- lymphoblasts as a model for the development of drug resistance in T-cell acute lymphoblastic leukemia. , 1985, Cancer research.
[39] R. McLendon,et al. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. , 1997, Cancer research.
[40] M. Herlyn,et al. Monoclonal antibodies in cell‐mediated cytotoxicity against human melanoma and colorectal carcinoma , 1979, European journal of immunology.
[41] R. McLendon,et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. , 1995, Cancer research.
[42] W. Cavenee,et al. Molecular biology of malignant degeneration of astrocytoma. , 1996, Pediatric neurosurgery.
[43] I. Fidler. Biological behavior of malignant melanoma cells correlated to their survival in vivo. , 1975, Cancer research.
[44] T. Roszman,et al. T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors. , 1997, Journal of immunology.
[45] G. Riethmüller,et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma , 1994, The Lancet.
[46] G. Brittinger,et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] P. Humphrey,et al. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[48] A. Glasebrook,et al. IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement. , 1980, Journal of immunology.